Inhibition of Antiviral CTL Responses by Virus-Infected Cells: Line Item Veto (Cells) Revisited by Rich, Robert F & Green, William R
Dartmouth College
Dartmouth Digital Commons
Open Dartmouth: Faculty Open Access Articles
4-20-2000
Inhibition of Antiviral CTL Responses by Virus-
Infected Cells: Line Item Veto (Cells) Revisited
Robert F. Rich
Dartmouth College
William R. Green
Dartmouth College
Follow this and additional works at: https://digitalcommons.dartmouth.edu/facoa
Part of the Medical Microbiology Commons
This Article is brought to you for free and open access by Dartmouth Digital Commons. It has been accepted for inclusion in Open Dartmouth: Faculty
Open Access Articles by an authorized administrator of Dartmouth Digital Commons. For more information, please contact
dartmouthdigitalcommons@groups.dartmouth.edu.
Recommended Citation
Rich, Robert F. and Green, William R., "Inhibition of Antiviral CTL Responses by Virus-Infected Cells: Line Item Veto (Cells)
Revisited" (2000). Open Dartmouth: Faculty Open Access Articles. 2867.
https://digitalcommons.dartmouth.edu/facoa/2867
MINIREVIEW
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Robert F. Rich* and William R. Green*,1
*Department of Microbiology and the Norris Cotton Cancer Center, Dartmouth Medical School,
1 Medical Center Drive, Lebanon, New Hampshire 03756
Received April 15, 2000; accepted April 20, 2000
It is widely acknowledged that the key immune re-
sponses providing protection against viral diseases are
neutralizing antibodies (Abs) and antiviral T cells, espe-
cially cytolytic T lymphocytes (CTL). Neutralizing Abs are
effective against free virions, particularly in reinfections
where preexisting Abs may protect against initial infec-
tion and/or memory Ab responses may be elicited with
sufficiently rapid kinetics to limit the infection after the
first few rounds of viral replication. In a complementary
fashion, antiviral CTL, via their ability to lyse virus-in-
fected cells and to secrete antiviral cytokines such as
IFN-g, are particularly important in defending against
viruses that are transmitted by infected cells and cell:cell
contact. CTL responses may also be critical in resolving
a primary encounter with virus before sufficient cycles of
infection have occurred to spread the virus systemically.
Because antiviral CTL are generally of the CD81 T cell
phenotype, the endogenous class I MHC antigen (Ag)
processing and presentation pathway, which monitors
the intracellular compartment for foreign insults and/or
for “danger,” is essential to recognition of virus-infected
cells by specific T cell receptors (TcR) of the CTL. Al-
though a thorough discussion of the molecular players of
the endogenous class I MHC pathway is beyond the
scope of this minireview, suffice it to summarize here that
the process begins with proteolytic cleavage of viral
proteins, typically in the multicatalytic proteasome com-
plex, followed by transport of peptides into the endoplas-
mic reticulum (ER) by a dedicated member of the ABC-
transporter family, the TAP-1/-2 heterodimer. In the ER
additional peptide trimming may occur. With the aid of
both general chaperonin molecules and specialized pro-
teins, such as tapasin, the ultimate trimolecular species
of b2-microglobulin, class I MHC heavy chain, and a
short (8–11 amino acid) minimal peptide epitope is
formed for export from the ER to the cell surface. The cell
surface presentation of the viral epitope in the polymor-
phic binding groove of the a1 and a2 domains of class I
heavy chain allows for identification of virus-infected
cells and accounts for the class I MHC-restricted nature
of CTL TcR recognition. Although the focus here will thus
be on classical CD81 CTL, it is important to emphasize
that antiviral CD41 T cells can also be crucial in the
resolution of viral infections: (1) some antiviral CTL are
class II MHC-restricted CD41 T cells; (2) Th1 CD41 T
cells can also have direct antiviral effects via cytokine
production and/or activation of effector macrophages; (3)
Th2 T cells provide help to B cell responses, particularly
for immunoglobulin class switching and affinity matura-
tion to produce high-affinity, neutralizing Abs; and (4)
most relevant to the present discussion, many antiviral
CD81 CTL responses are dependent on CD41 Th, prin-
cipally to “condition” or “mature” professional antigen-
presenting cells (APC) so that they will more efficiently
stimulate/costimulate naive CD81 antiviral CTL and/or to
produce cytokines such as IL-2 to maximally drive CD81
CTL expansion. Thus, to the extent that antiviral CD41 Th
are also involved, the efficient functioning of the alterna-
tive exogenous pathway of viral antigen processing and
presentation by class II MHC may also be critical.
To combat recognition of virus-infected cells by CD81
CTL, viruses have developed a number of clever evasion
strategies. These escape mechanisms fall into two main
classical categories: (1) variation in viral amino acid
sequences responsible for epitope production and (2)
viral genome encoding of proteins that actively interfere
with the production and presentation of unmutated viral
epitopes. Both of these general evasion strategies have
been discussed in detail in a number of recent review
articles. Here we simply emphasize that for variations
directly affecting viral epitopes per se, evidence has
accumulated not only for changes within the epitopes to
inhibit binding to MHC class I alleles or by the TcR, but
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also for alterations in the amino acid flanking sequences,
resulting in impaired processing of the epitopes from
their precursor proteins/larger peptides. On the other
hand, for viral proteins that inhibit epitope processing or
presentation, it is conceptually possible that every step
of the endogenous class I pathway may provide an
opportunity for a virus countermeasure and escape from
antiviral T cells. Indeed, several reports demonstrate that
an increasing number of the host cell molecular players
have apparently been targeted by viral proteins. These
studies range from the early identification of the adeno-
virus E3/19K protein that retains certain class I alleles in
the ER to more recent descriptions of a variety of viral
proteins encoded particularly by the large-genome DNA
viruses, such as the Herpes family, that interfere with not
only transport of MHC/peptide complexes from the ER,
but also other steps of the presentation pathway, such as
the TAP-1/-2 transporter. In addition, in those cases
where CD41 T cells are also crucial for antiviral immu-
nity, it seems likely that viral evasion strategies will be
uncovered that target various points within the exoge-
nous class II MHC processing and presentation path-
way. Collectively, the importance of T cell-mediated im-
munity to the successful resolution of viral infections is
underscored by these examples of T cell epitope varia-
tion and viral molecular inhibitors of host cell antigen
processing and presentation.
In this minireview we explore an alternative general
mechanism by which viruses, specifically as virus-in-
fected cells, may escape clearance by antiviral T cell-
mediated immunity—the ability of virus-infected cells to
serve as “veto cells” that inactivate activated antiviral T
cells. The principal differences between the virus escape
mechanisms discussed above and the veto cell strategy
are that in veto cell inhibition (1) viral epitopes recog-
nized by the T cells are not modified, (2) viral epitope
processing and presentation are not disturbed, and (3)
TcR recognition and the initiation of the T cell response,
and perhaps initial clonal expansion of antiviral T cells,
are not inhibited. Rather, the veto cell mechanism em-
braces and takes advantage of normal antigen process-
ing and presentation and MHC-restricted TcR recogni-
tion. In short, the virus-infected veto cell is a bona fide
APC, but one which, subsequent to its specific recogni-
tion and binding by the antiviral T cell, functionally inac-
tivates, or causes the apoptotic lysis of, that antiviral T
cell. In the discussion that follows we will first reexamine
the roots of veto cell regulation of nonviral specific CTL
responses as first reported more than two decades ago
and then merge and extend these concepts of inhibitory
APC into the context of evidence for veto cells as a virus
escape mechanism.
In 1979 R. G. Miller and collaborators first coined the
term “veto cells” to explain the specific inhibition or ve-
toing of allo-MHC-specific CTL responses by cells bear-
ing the allogeneic MHC. A series of studies by this group
and other investigators over the next several years con-
firmed the concept of veto cells and distinguished them
from T suppressor (Ts) cells and other inhibitory immune
phenomena (see the review by Fink et al., 1998). Thus,
veto cells were highly specific, importantly at the effector
phase in contrast to many then current reports of Ts
cells, which were induced in an antigen-specific way but
whose effector suppression was delivered in an antigen-
nonspecific manner. Similarly, veto cell action depended
on cell:cell contact between the veto cells and the re-
sponder T cells that were inactivated, and soluble inhib-
itory factors could not be identified that could account for
veto cell function. Indeed, the hallmark characteristic of a
veto cell was the exquisite specificity of its interaction
with T cells—a degree of specificity that could be rec-
onciled only with TcR recognition of the veto cell by the
antigen-specific T cells about to be inactivated. Thus,
veto function was extended from the early allo-MHC CTL
systems to inhibition of both MHC-restricted anti-minor
histocompatibility (H) antigen and anti-hapten CTL
responses.
With respect to the phenotype of the veto cell in these
early studies, the focus was on CD81 T cells/CTL. De-
pending on the specific system, CD81 CTL were fre-
quently either the predominant or only veto cell type
identified, or they were at least the most efficient kind of
veto cell. Although a complete mechanism for inactiva-
tion by veto cells could not be proposed at this early
stage, it appeared that the final result of veto cell action
was the loss of the antigen-specific CTL. Thus, using the
only method then available to enumerate antigen-spe-
cific T cells, limiting dilution analysis (LDA) which scores
precursor CTL (pCTL), greatly diminished frequencies of
pCTL were observed when veto cells were present.
However, despite the predominant CD81 CTL phenotype
of veto cells and this apparent lysis of antigen-specific
pCTL, there was no experimental support for the obvious
possibility that veto cells lysed pCTL by using the stan-
dard CTL lytic mechanism used to kill target cells. To be
sure, engagement of the CD81 veto cell TcR, which,
except in certain contrived circumstances, is a prerequi-
site for activation of the effector cell lytic mechanism of
CTL, was not required for veto cell function. That the CD8
molecule was not just a marker of the most efficient veto
cell population, but was relevant to veto cell function,
however, was shown in a series of papers by Miller and
colleagues and other investigators (see below). In fact,
the emphasis on CD8 positivity of veto cells led some
early investigators to consider CD81 T cells as the only
veto cells or, as is more common currently, as the “classic
veto cells.”
As these early studies were extended through the mid
1980s, it became clear that various cells of phenotypes
other than CD81 T cells possessed such APC inhibitory
activity on antigen-specific T cells. These cell types in-
cluded bone marrow and spleen cells from nude (athy-
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mic) mice. From normal euthymic mice evidence for veto
cell activity was reported for bone marrow cells—includ-
ing both non-T and non-B cells as well as derived T cell
colonies, thymus cells (both lymphoid colonies and thy-
mic epithelium), fetal liver cells and lymphoid colonies
grown from fetal liver, and activated spleen cells. More
recently, veto-type activity has also been reported for an
even wider range of cell types. Given that many of these
cells are CD8-negative, and/or may inactivate more ma-
ture T effector cells instead of, or in addition to, pCTL,
one could debate whether these cell types should be
considered (classic) veto cells. In many cases T cell/CTL
lysis by this expanded list of cells with veto-like activity
has been shown to be due to veto cell expression of
FasL (CD95L), in addition to the specific MHC/peptide
complexes recognized by the T cells, with triggering of
apoptotic lysis of Fas (CD95)-positive activated T cells.
Here, we will use the term “veto cell” in the broadest
context of any cell that lyses or irreversibly inactivates an
antigen-specific T cell in a contact-dependent manner
driven by TcR recognition of the veto cell, regardless of
the phenotype of the veto cell (including CD8 status) or
the molecular mechanism of veto cell-induced lysis/in-
activation. In this light, there is evidence for veto cell
activity and/or FasL expression (implicating potential
veto activity) by various tumor types associated with
melanoma, hepatocellular carcinoma, esophageal carci-
noma, astrocytoma, colon cancer, T cell acute lympho-
cytic leukemia, chronic myeloid leukemia, acute myelo-
blastic leukemia, multiple myeloma, and natural killer
cell lymphoma/large granular lymphocytic leukemia.
In our own recent studies of veto cell inhibition of CTL
responses to “AKR/Gross” endogenous murine leukemia
virus (MuLV)-encoded epitopes, CTL-nonresponder
AKR.H-2b congenic mice contained highly specific veto
cells of the CD81 T cell, CD41 T cell, and B cell subsets.
No evidence could be obtained for veto cell activity in the
splenic macrophage population, however, despite their
viral antigen positivity, like that of these three lymphoid
veto cell populations. The same phenotypic subsets of
inhibitory cells were found whether veto activity was
measured by in vivo adoptive transfer experiments at the
level of CTL priming or by in vitro coculture at the level of
secondary antigenic restimulation. Thus, our data indi-
cate that some (B cell) but not necessarily other (macro-
phage) members of the APC populations referred to as
“professional APC” may have functional veto activity in
this MuLV system. Of particular interest—given the cur-
rent consensus that the third member of the professional
APC group, dendritic cells (DC), is the most efficient
stimulatory APC—recent studies by other laboratories
have indicated that a DEC-2051 DC subpopulation can
function as veto cells of allo-MHC responses. Implicit in
these studies of MHC class II-positive veto cells, which
can therefore display both cell surface class I/ and class
II/foreign peptide complexes, is at least the potential to
also veto CD41 antigen-specific T cells. For example, in
our MuLV system, in which optimal antiviral CTL produc-
tion requires CD41 T cells, veto activity restricted against
either only the CD41 or the CD81 responder T cell
compartment was sufficient to similarly and dramatically
inhibit antiviral CTL generation. Similarly, in the allo-MHC
veto cell system, CD41 T cell responses were directly
shown to be inhibited by the DEC-2051 DC subpopula-
tion.
In the context of the present broad definition of veto
cells encompassing several different virus-infected cell
types that may inactivate antiviral CD41 Th and/or CD81
pCTL/CTL, it is not unreasonable to speculate that there
may be different veto molecular mechanisms. At least
conceptually, these mechanisms may range from irre-
versible functional inactivation to lysis per se of the
antiviral T cell. As for lytic veto mechanisms, both our
anti-MuLV system and the DEC-2051 DC system have
been shown to be essentially totally dependent on FasL/
Fas interactions, with veto cell FasL triggering the
apoptotic lysis of Fas1 T cells that recognize the veto
cell. In these murine settings, this has been convincingly
shown by comparing antigen-specific responding T cells
from wild-type vs lpr- (Fas2) or gld- (FasL2) congenic
mice for susceptibility to veto cell inhibition. The results
implicating a FasL/Fas-mediated mechanism (veto in-
susceptibility of only Fas2 responder T cells) were con-
firmed with blocking reagents directed at one or both
members of this interacting molecular pair—i.e., Fas–Ig
fusion protein in our system—to inhibit the lysis of anti-
viral T cells mediated by veto cells and restore T cell
responsiveness. We have further utilized in vitro recon-
stitution of isolated, antigen-primed CD41 Th vs CD81
pCTL populations from wild-type vs Fas2 congenic
strains to limit Fas expression to one or the other T cell
subpopulation. By these means, the substantial (25- to
70-fold) reductions in polyclonal antiviral CTL activity
and/or pCTL expansion (by LDA determinations) were
achieved by veto targeting of either CD41 or CD81 anti-
viral T cells, or both. The ability of CD41 Th cells to be
vetoed was consistent with our identification of class II
retroviral antigen-expressing veto B cells and with recent
evidence that activated murine B cells and other
B-lineage cells express FasL.
Taking all these findings into consideration, we pro-
pose an updated set of related models of veto cell action
to explain the inactivation of antigen-specific CD41 and
CD81 T cells, both generally and specifically in the case
of antiviral T cells (Fig. 1). Thus, CD81 pCTL/CTL can be
vetoed by any virus-infected class I MHC-positive cell
that also expresses, or can be induced to express, the
inhibitory machinery [here depicted as simply cell sur-
face FasL (CD95L) expression], with or without CD8 (Fig.
1A). In contrast, antigen-specific CD41 Th can be vetoed
only by virus-infected class II-positive APC, such as DC
that may express CD8 (Fig. 1B) or B cells, which are
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CD82 (Fig. 1C). In each case the first step in the cellular
interaction is governed by recognition of veto cell class I
or II MHC/viral peptide complexes by the TcR of the
activated antiviral T cell. It is the exquisite specificity of
TcR recognition that accounts for the precision of the
apparent veto cell “backward recognition” and veto cell-
mediated inactivation. Indeed, in our murine retrovirus
model, spleen cells from AKR.H-2b mice that spontane-
ously express endogenous MuLV inhibit the secondary
in vitro stimulation of the anti-MuLV CTL response that is
dominated by a Kb-restricted p15E viral envelope peptide
(KSPWFTTL) specificity, but not a “third-party” minor H
specific CTL response. This is the case even when the
same responder T cell population, primed against both
sets of antigens, is cultured in the same well with
AKR.H-2b veto cells and a given positively stimulating,
irradiated tumor cell that expresses both viral and minor
H antigens.
In the case of veto cells that express CD8, the second
step is engagement of nonpolymorphic residues of the
a3 domain of class I MHC of the TcR-bound antiviral T
cell, whether this is a CD81 pCTL/CTL (Fig. 1A) or a
CD41 Th (Fig. 1B). As alluded to above, early studies that
focused on inactivation of pCTL by classic CD81 veto
FIG. 1. A schematic depiction of veto cells with three different basic
phenotypes and a representation of the sequential kinetic events lead-
ing to the vetoing of “targeted” T cells. Shortly following (or coincident
with) the initial Ag/TCR interaction, veto cells that express CD8 mole-
cules may ligate CD8 to a3 domains of MHC class I complexes on the
targeted T cell and contribute to the initiation of a signaling cascade
leading to functional inactivation (or here, apoptotic lysis) of the tar-
geted T cell. One molecular lytic mechanism is depicted here: the
interaction of veto cell FasL with the Fas death receptor of the targeted
T cell, initiating a cascade of caspases and eventual apoptosis. In other
cases where veto cells are CD82, veto activity is by definition CD8
independent, thus indicating that signaling through class I of the
targeted T cell is not essential.
FIG. 2. Concurrent inhibition of antiviral CTL activity and reduction in
the frequency of tetrameric MHC class I/peptide complex binding by
specific CD81 CTL. B6 mice were inoculated with AKR/Gross MuLV1
tumor cells. Eleven days later, responder lymphocytes were cultured in
mixed lymphocyte tumor cell cultures (MLTC) for 6 days with irradiated,
viral Ag1 tumor cells, without (a, b) or with (c, d) AKR.H-2b veto cells. At
the end time point of the MLTC, responder cells were tested for their
ability to lyse 51Cr-labeled viral Ag1 tumor target cells and were con-
currently stained via flow cytometric analysis to identify and enumerate
Kb/KSPWFTTL tetramer [phycoerythrin (PE)-labeled] and anti-CD8a
mAb [allophycocyanin (APC)-labeled] binding to CTL. Responder T
cells which were CD8a1 but did not bind the tetramer are shown as
green data points in the lower right quadrants (b, 23%; d, 27%). CD8a1/
tetramer1 (double positive) T cells are shown as orange data points in
the upper right quadrants (b, 10%; d, 3%). Thus, the percentage of CD81
T cells that are tetramer1 is 30% (b) versus 10% (d).
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cells suggested that recognition of responder T cell
class I a3 domains by CD8, in conjunction with simulta-
neous T cell TcR engagement, is necessary and suffi-
cient for veto cell function. Consistent with this hypoth-
esis, mAbs to the a3 domain of responder T cell class I
could inhibit the development of allogeneic CTL re-
sponses, and this effect was extended to Th responses
in mixed lymphocyte responses, apparently in both
cases due to responder T cell apoptosis. Furthermore,
there was evidence from peripheral T cell deletion stud-
ies that CD8 with an intact cytoplasmic tail was required
for veto cell function. These studies suggested that per-
haps cell surface-initiated signaling cascades within
both the veto cell and the target T cell might be crucial,
but to our knowledge there were no additional data to
advance a specific molecular model that connected
these putative signals to a triggering of T cell apoptosis.
We suspect that activation of the veto cell is required
and that in many cases the end result of such induced
signaling pathways is the induction of expression, or the
upregulated expression, of veto cell surface FasL. The
signals culminating in increased FasL expression may
emanate from veto cell class I upon its ligation by the
TcR and/or from veto cell CD8, in the case of CD81 veto
cells, as just discussed. However, we believe it unlikely
that signaling from the cytoplasmic domain of CD8 is
absolutely required: (1) clearly some veto cells are CD82
(Fig. 1C), and (2) in other cases it has been shown that
CD81 veto cells may not necessarily employ CD8 in the
veto cell mechanism (Figs. 1A and 1B). Thus, in the case
of the DEC-2051 veto cell DC population, this subset was
initially thought to be functionally defined by the expres-
sion of CD8a. Subsequently, using CD8 knockout mice, it
was discovered that CD8 expression was irrelevant to
the veto function of the CD8a1 DC and that the coex-
pressed DEC-205 marker also defined this negative reg-
ulatory DC subpopulation. Alternatively, or in addition, it
is possible that veto cells, perhaps particularly virus-
infected veto cells, have some constitutive expression of
FasL, but at a level that is insufficient to trigger the
apoptosis of Fas1-activated T cells. Given recent evi-
dence that reciprocal signaling can occur through FasL
following its ligation of Fas, there could be a positive
feedback signaling loop through which veto cell FasL
expression is increased to levels that allow delivery of a
death signal through Fas (step 3, Fig. 1) to cause the
apoptotic lysis of the activated T cell.
Whatever the exact pathways of signal transmission in
the veto cell, the concept of veto cell activation and
induction of signal transduction is consistent with two
widely observed characteristics of veto cell function.
First, in studies to date, functional veto cells must be
viable and metabolically active—veto cells that have
been irradiated, or treated with the irreversible protein
synthesis inhibitor emetine (our unpublished experi-
ments), are not able to inhibit specific T cell responses.
Second, the delayed kinetics of veto cell action in in vitro
restimulation systems may, at least in part, be due to a
requirement for veto cell activation. In our antiendog-
enous MuLV CTL system, where AKR.H-2b veto cells are
added to 6-day in vitro CTL restimulation cultures, kinet-
ics experiments have suggested that veto cell-induced T
cell inactivation is occurring primarily on days 2 and 3.
This time frame is very consistent with other studies,
including the CD41 Th and CD81 CTL allo-MHC re-
sponses studied in MLR cultures by Miller and collabo-
rators. In these early studies, these delayed kinetics
were interpreted as indicative that the T cell target sus-
ceptible to veto inactivation was neither an unactivated,
naive pCTL or pTh nor a fully differentiated effector T cell,
but rather a precursor T cell that was at the early stages
of activation or clonal expansion. In the context of FasL/
Fas-dependent veto cells, our view is that while re-
sponder T cell activation is necessary, if nothing else to
induce or augment the expression of Fas on the re-
sponder T cell surface, it seems likely that the kinetics of
veto cell-mediated T cell apoptosis also depend on the
time frame of veto cell activation. Our preliminary exper-
iments have shown a gradual increase in Fas expression
by the responder T cell population over the course of the
6-day restimulation cultures. In contrast, FasL is known
to be a very transiently expressed activation molecule.
Thus, it would follow that the optimal time for veto cell
inhibition is a complex phenomenon that may depend on
both the time needed for the T cell and the veto/APC cell
to reciprocally activate each other and the kinetics and
duration of expression of those activation molecules on
both cell types required for full veto function. Although
the focus here has been on FasL/Fas, certainly the ex-
pression of the required veto cell MHC class I/II–peptide
complexes and T cell TcR will play determining roles, as
well as potentially other molecules, such as adhesion
molecule receptors/coreceptors.
A limitation in the studies of veto cell inhibition of
antigen-specific, polyclonal T cell responses to date has
been the inability to enumerate and identify all the anti-
gen-specific T cells that would potentially be susceptible
to veto cell inactivation. LDA determination of pCTL fre-
quencies has been employed, but LDA requires that an
antigen-specific T cell be able to undergo several rounds
of division upon activation to be scored and thus will not
detect terminally differentiated effector T cells. Indeed,
the more recently introduced techniques of ELISPOT
analysis for cytokine (usually IFN-g for CD81 CTL) se-
cretion and the use of tetrameric class I MHC/peptide
complexes in flow cytometric analyses have yielded fre-
quencies of antigen-specific T cells that are generally at
least 10-fold, and sometimes approaching 100-fold,
higher than those obtained by LDA. This is logical since
at the height of an immune response one would expect
that the overwhelming majority of the clonally expanded
T cells would be terminally differentiated effector cells.
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Use of class I tetramers loaded with a given immuno-
dominant epitope has proven to be a particularly effec-
tive approach that is readily amendable to further anal-
ysis of the antigen-specific T cells on an individual basis
by taking advantage of the power of multicolor flow
cytometry. In our antiendogenous MuLV CTL system we
have conducted a set of initial experiments with Kb class
I tetramers loaded with the immunodominant peptide
epitope KSPWFTTL that is encoded by the p15E portion
of the retroviral env gene. By integrating this technique of
Ag-specific pCTL/CTL identification into the context of a
functional veto cell inhibition experiment, we have been
able to show corresponding veto cell-dependent de-
creases in the generation of polyclonal antiviral CTL
activity and the frequency of these effector CD81 T cells
(Fig. 2). Thus, at day 6 of the CTL restimulation cultures
the observed 70–80% inhibition of the development of
specific antiviral CTL activity caused by inclusion of
endogenous viral antigen-positive AKR.H-2b veto cells
(compare Figs. 2a and 2c) was matched by the approx-
imate 70% reduction in the percentage of CD81 T cells
that specifically bound the Kb tetrameric complexes dis-
playing the immunodominant KSPWFTTL epitope (com-
pare the two-color analyses of Figs. 2b and 2d). Further
analyses incorporating staining for CTL activation mark-
ers, such as Fas, and indicators of apoptosis such as
annexin V staining or the flow cytometric modification of
the TUNEL assay are ongoing and should permit us to
examine the CTL restimulation cultures at various times
to directly visualize and enumerate the veto cell-depen-
dent apoptosis of antiviral CTL specific for the immuno-
dominant or other subdominant epitopes. By these
means and others our intent is to fully characterize the
mechanism of FasL/Fas-mediated veto cell lysis of anti-
viral CD41 Th and CD81 CTL in the endogenous MuLV
system. A particularly important issue to examine is the
tantalizing possibility that retrovirus infection and expres-
sion either may cause the upregulation of FasL expres-
sion so that it is constitutive on virus-infected cells or
may alter the signal transduction pathways that regulate
FasL expression such that activation of veto cells leads
to increased cell surface FasL.
In summary, we propose veto cell inactivation of anti-
gen-specific antiviral T cells as another mechanism of
virus escape from T cell-mediated immunity. Although
there was early speculation that viruses might employ
the veto strategy, this has remained an understudied
area. Among the reports on viral veto cells in addition to
our MuLV system there have been suggestions in the
context of retrovirus-caused immunodeficiency, includ-
ing evidence that CD41 T cells infected with SIV show a
nef-dependent induction of FasL expression which cor-
related with the death of SIV-specific CTL. Whether FasL/
Fas-mediated apoptosis of CD41 T cells is responsible
for the decline of CD41 T cells in HIV/AIDS has been the
subject of much debate and controversy, let alone the
possible role of HIV-infected veto cell FasL-dependent
apoptosis of antiviral T cells. However, there are several
indications that veto cells can have significant inhibitory
functions in vivo. These include both experimental and
clinical systems such as peripheral tolerance and bone
marrow transplantation-induced tolerance, as well as
spontaneous examples of T cell nonresponsiveness. In
the latter category we would offer our system of the
natural CTL nonresponsiveness against endogenous
MuLV in MHC responder strains which express these
endogenous MuLV and have virus-infected veto popula-
tions, as assessed by both in vivo adoptive transfer and
in vitro cell-mixing experiments, as discussed above. In
addition and beyond the scope of virus infections, there
have been several reports over the past few years indi-
cating that, for at least some immunologically privileged
tissues, veto cell inhibition may help to maintain this
reduced immunological status. These tissues include the
anterior chamber of the eye and the testes, where FasL-
bearing stroma cells and Serotoli cells, respectively, may
serve as veto cells to cause the apoptotic lysis of acti-
vated T cells entering these confined spaces before
inflammatory damage is caused to these sensitive sites.
Finally, it is perhaps instructive to consider that virus-
infected veto cells may represent an example of a “fail-
safe” ultimate escape mechanism obtained by coopting a
normal immunological process. Thus, the needed down-
regulation of the large number of effector T cells, once an
infection has been successfully cleared, is generally
considered to be accomplished by a process referred to
as activation-induced cell death (AICD). In AICD acti-
vated T effector cells expressing FasL and/or Fas un-
dergo apoptotic lysis by either “suicide” or “fratricide”
upon engagement of FasL and Fas in an antigen-non-
specific manner, although the involvement of other TNF/
TNFR family members has also been described. AICD
has been most readily demonstrated in situations in
which there are very high frequencies of activated T
cells, such as by superantigen-induced expansion of TcR
Vb classes or by use of TcR-transgenic mouse models.
We speculate that in cases where the frequency of anti-
gen-specific T cells is more normal during the develop-
ment of typical polyclonal responses, cell:cell interac-
tions initiated only by FasL/Fas ligation may be relatively
inefficient. However, virus infection leading to presenta-
tion of viral peptides by MHC class I and/or II would
overlay TcR recognition onto the system to substantially
increase the efficiency of cell:cell interactions and render
them antigenically specific. Providing that the infected
cells have the inherent ability to express FasL, or via the
possibility the viral expression enhances FasL expres-
sion, a veto cell would be formed that could serve as a
back-up escape device if the various viral strategies to
mutate T cell epitopes or interfere with epitope process-
ing have failed. If the virus-infected veto cells are present
before substantial polyclonal T cell expansion and differ-
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entiation to effector cells has occurred, the T cell re-
sponse could thus essentially be “nipped in the bud.”
Further experimentation will obviously be required to
determine whether virus-infected veto cells are physio-
logical mediators of T cell low/nonresponsiveness in the
viral systems analyzed so far and whether this concept
can be extended to other viruses as a mechanism to
escape T cell immunity.
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